edema/hypoxia

TECHNICAL FIELD The present invention relates to the use of N-acetyl-D-glucosamine and pharmaceutical acceptable salts thereof in the manufacture of a medicament for resisting cardiac and cerebral ischemia as well as oxygen-deficiency. BACKGROUND ART The cardiac and cerebral ischemia as well as

TECHNICAL FIELD Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their

TECHNICAL FIELD Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their

BACKGROUND OF THE INVENTION This invention relates to the use of protein S and/or variants thereof as neuroprotective agents for treating brain disorders and other pathological conditions. The ability of protein S and variants thereof to act as cell survival factors on cells of the nervous systems

TECHNICAL FIELD OF THE INVENTION The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and compositions for

TECHNICAL FIELD OF THE INVENTION The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for

The present invention relates to the field of ophthalmology. In particular, the present invention relates to the treatment of retinal tissues. More specifically, the present invention discloses compositions and methods of using adenosine uptake inhibitors in the prevention or treatment of retinal

The invention relates to novel 15-nitro-2.beta., 3.beta.-dihydro-and 15-nitro-2.beta., 3.beta., 6, 7-tetrah (according to the Chemical Abstracts' nomenclature 15-nitro-(2.alpha., 5.alpha., 12.beta., 19.alpha.)-aspidospermidine-3.alpha.-carboxylic acid derivatives) of the formula (I), ##STR2##

CROSS REFERENCE TO RELATED APPLICATION The present invention is based on, and claims priority from 60/008,390, filed Dec. 8, 1995. BACKGROUND OF THE INVENTION This application is directed to inhibitors of nitric oxide synthase, and in particular substituted azacycle derivatives. Nitric Oxide in

BACKGROUND OF THE INVENTION This application is directed to inhibitors of Nitric oxide synthase, and in particular cyclic amidines. Nitric Oxide in Biology. The emergence of nitric oxide (NO), a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a U.S. National Stage Application under 35 U.S.C. .sctn. 371 of International Application No. PCT/CN2015/076528, filed Apr. 14, 2015, which application claims priority to Chinese Patent Application No. 201410170263.7 filed Apr. 25, 2014,

FIELD OF THE INVENTION The present invention describes novel methods to induce synthesis of endogenous nitric oxide or endothelium-derived relaxing factor, and methods for maintaining levels of nitric oxide under hypoxic conditions. One aspect of the invention relates to novel methods to induce